<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778556</url>
  </required_header>
  <id_info>
    <org_study_id>130057</org_study_id>
    <secondary_id>13-DK-0057</secondary_id>
    <nct_id>NCT01778556</nct_id>
  </id_info>
  <brief_title>Short-term Effects of Leptin in People With Lipodystrophy</brief_title>
  <official_title>Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Lipodystrophy is a condition where people do not have enough fat in the body. People with
      lipodystrophy can have problems such as diabetes or an enlarged liver. Researchers are
      looking at how leptin, a hormone produced by fat cells, can help people with these problems.
      Leptin helps control appetite and how the body stores food. Taking leptin can help people
      with lipodystrophy eat less food, which may help treat diabetes and other problems. To better
      understand how leptin works, researchers want to do an inpatient study on leptin treatment in
      people with lipodystrophy.

      Objectives:

      - To study how leptin treatment affects lipodystrophy.

      Eligibility:

      - Individuals between 14 and 70 years of age who have lipodystrophy.

      Design:

        -  All participants will have a 19-day stay at the National Institutes of Health Clinical
           Center. One group of participants will have tests for 5 days before starting to take
           leptin. They will then take leptin for 2 weeks, and have more tests. The other group of
           participants will have tests for 5 days while taking leptin. They will then take stop
           taking leptin for 2 weeks, and have more tests, and then they will start taking leptin
           again.

        -  Participants will have regular blood and urine tests during the visit. Some of the blood
           tests will look at insulin levels. Some will look at how the body metabolizes sugar and
           fat. Other tests will check hormone levels, especially of reproductive hormones.

        -  During the visit, participants will spend 3 separate days in a metabolic chamber, a
           special room that measures how many calories the body uses. Urine samples will be
           collected during these stays.

        -  Participants will also have several body imaging studies, including magnetic resonance
           imaging and a body composition scan.

        -  Physical activity will be tested with an exercise bicycle and an electronic activity
           monitor.

        -  Participants will be asked questions about hunger and comfort levels throughout the
           stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue
      to the rest of the body conveying information about long-term nutritional status. Patients
      with lipodystrophy have leptin deficiency secondary to lack of adipose tissue, and thus
      represent a natural model for studying the effects of leptin deficiency and replacement in
      humans. Leptin replacement in lipodystrophy ameliorates metabolic and endocrine
      abnormalities, including reducing food intake, improving insulin resistance and diabetes,
      reducing ectopic lipid, and normalizing reproduction. The reduction in energy intake induced
      by leptin replacement is likely responsible for part of the improvements observed in glucose
      and lipid metabolism. The clinical effects of leptin that are independent of changes in
      energy intake, and the mechanisms underlying these effects, have been poorly explored in
      humans.

      Aim

      The primary aim of this study is to determine the energy intake-independent effects of leptin
      on energy metabolism in lipodystrophic subjects. The major aspects of energy metabolism to be
      studied are:

        1. Lipid metabolism, including fasting lipids, lipolysis and fatty acid turnover, and
           ectopic lipid storage.

        2. Glucose metabolism, including fasting glucose, endogenous glucose production, and
           insulin sensitivity

        3. Energy expenditure, including total and resting energy expenditure, skeletal muscle work
           efficiency, and spontaneous physical activity

      In addition, the effects of leptin on endocrine and autonomic function will be examined,
      including effects on the thyroid, gonadal, and adrenal axes, as well as blood pressure, body
      temperature, and heart rate variability.

      Methods

      This is a non-randomized, parallel group study. Two groups of patients aged 14 to 70 years
      with lipodystrophy will be studied: leptin naive and leptin treated. Minors will only be
      included in the leptin naive arm. All subjects will be stabilized on a weight maintenance
      diet for 5 days (Period 1). After this, leptin will be withdrawn from leptin treated
      subjects, and leptin will be initiated in leptin naive subjects for a period of 14 days
      (Period 2). The same isocaloric diet will be continued throughout both Periods, permitting
      study of leptin s effects independent of energy intake.

      All subjects will undergo metabolic testing on admission, at the end of Period 1, and
      throughout Period 2, to generate a detailed short-term time course of the effects of leptin
      initiation or withdrawal. At the end of Period 2, leptin will be continued in the leptin
      naive subjects, and restarted in the leptin treated subjects. Repeat metabolic testing will
      be performed 6-12 months after leptin initiation in the leptin-naive cohort to generate
      information on leptin s long-term effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 26, 2013</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Body Insulin Sensitivity</measure>
    <time_frame>Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)</time_frame>
    <description>Total body insulin sensitivity (measured as glucose disposal rate during a hyperinsulinemic, euglycemic clamp)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin-mediated Suppression of Hepatic Glucose Production</measure>
    <time_frame>Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)</time_frame>
    <description>Hepatic insulin sensitivity (measured as suppression of endogenous glucose production during a hyperinsulinemic, euglycemic clamp)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous Rate of Appearance of Palmitate</measure>
    <time_frame>Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)</time_frame>
    <description>Endogenous Rate of Appearance of Palmitate is measured in plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Leptin naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studied for 5 days without metreleptin, then 14 days while taking metreleptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On-leptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Metreleptin</intervention_name>
    <description>Recombinant analog of the human hormone, leptin</description>
    <arm_group_label>Leptin naive</arm_group_label>
    <arm_group_label>On-leptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Age 14-70 years (children under age 18 will only be enrolled in the leptin-naive arm
             of the study

          -  Clinically-significant lipodystrophy as defined in protocol 02-DK-0022 (Long Term
             Efficacy of Leptin Replacement in the Treatment of Lipodystrophy). Relevant inclusion
             criteria for enrollment in protocol 02-DK-0022 are (summarized):

               -  Lipodystrophy identified by the study physician during physical examination as an
                  absence of fat outside the range of normal

               -  Circulating leptin levels &lt; 12.0 ng/mL in females and &lt; 8.0 ng/mL in males

               -  Presence of at least one of the following metabolic abnormalities:

                    1. Diabetes as defined by the 2007 American Diabetes Association criteria

                    2. Fasting insulin &gt;30 microU/mL

                    3. Fasting hypertriglyceridemia &gt;200 mg/dL

          -  Co-enrolled in protocol 02-DK-0022 and either:

               -  Leptin naive, with plans to initiate leptin treatment during the current study.
                  For the purpose of this study, leptin naive will be defined as having received no
                  exogenous leptin in the 4 months prior to study participation. Thus, subjects who
                  previously received leptin therapy, discontinued, and wish to restart are
                  eligible.

        Or

        --Leptin treated, meaning the subject has taken a stable dose of exogenous leptin for a
        minimum of 4 months (adults over age 18, only)

        EXCLUSION CRITERIA:

        In leptin treated subjects only, the following exclusion criteria apply:

          -  Poorly controlled diabetes at study entry (hemoglobin A1c greater than or equal to 9%)

          -  Poorly controlled hypertriglyceridemia at study entry (serum triglycerides &gt; 800
             mg/dL)

          -  Extreme hypertriglyceridemia prior to leptin (triglycerides greater than 2000 mg/dL at
             initiation of leptin treatment)

          -  History of chronic or recurrent acute pancreatitis (&gt; 1 episode), or a single episode
             of pancreatitis while receiving leptin treatment

          -  Lipase greater than the upper limit of normal (491 units/L) at study entry

        In all subjects (leptin treated and leptin naive), the following exclusion criteria apply:

          -  Known HIV infection or HIV-associated lipodystrophy

          -  History of diabetic ketoacidosis

          -  Active inflammatory disease (e.g. dermatomyositis)

          -  Change in diabetes or lipid-lowering medications within the past 6 weeks

          -  Estimated glomerular filtration rate &lt; 30 mL/minute

          -  Current or recent (past 2 weeks) use of systemic glucocorticoids

          -  Inadequately controlled hypothyroidism (TSH &lt; 0.4 or &gt;4 mcIU/L) or change in thyroid
             medication in the past 8 weeks.

          -  Pregnancy or breast-feeding

          -  Psychiatric disorder impeding competence or compliance

          -  Any medical condition or medication that will increase risk to the subject (e.g.
             ischemic heart disease, decompensated liver disease) or that will interfere with
             interpretation of study data (e.g. Cushing s syndrome).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca J Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-DK-0057.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier JS. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest. 1997 Feb 1;99(3):391-5.</citation>
    <PMID>9022071</PMID>
  </reference>
  <reference>
    <citation>Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature. 1996 Jul 18;382(6588):250-2.</citation>
    <PMID>8717038</PMID>
  </reference>
  <reference>
    <citation>Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996 Mar;12(3):318-20.</citation>
    <PMID>8589726</PMID>
  </reference>
  <verification_date>February 25, 2019</verification_date>
  <study_first_submitted>January 26, 2013</study_first_submitted>
  <study_first_submitted_qc>January 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>June 24, 2019</results_first_submitted>
  <results_first_submitted_qc>October 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2019</results_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipodystrophy</keyword>
  <keyword>Leptin</keyword>
  <keyword>Energy Expenditure</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT01778556/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leptin Naive</title>
          <description>Studied for 5 days without metreleptin, then 14 days while taking metreleptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="P2">
          <title>On-leptin</title>
          <description>Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention 2 (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0">no long-term follow-up period in on-leptin arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0">no long-term follow-up period in on-leptin arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>noncompliance with metreleptin</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leptin Naive</title>
          <description>Studied for 5 days without metreleptin, then 14 days while taking metreleptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="B2">
          <title>On-leptin</title>
          <description>Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="17"/>
                    <measurement group_id="B2" value="25" spread="6"/>
                    <measurement group_id="B3" value="28" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of lipodystrophy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Generalized</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subtype of lipodystrophy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Congenital generalized lipodystrophy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Familial partial lipodystrophy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acquired generalized lipodystrophy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endogenous leptin level</title>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="10.2"/>
                    <measurement group_id="B2" value="1.2" spread="0.5"/>
                    <measurement group_id="B3" value="7.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Body Insulin Sensitivity</title>
        <description>Total body insulin sensitivity (measured as glucose disposal rate during a hyperinsulinemic, euglycemic clamp)</description>
        <time_frame>Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)</time_frame>
        <population>One patient at Period 2 (14 days) in Leptin naive arm was withdrew due to protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>Leptin Naive</title>
            <description>Studied for 5 days without metreleptin, then 14 days while taking metreleptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
          </group>
          <group group_id="O2">
            <title>On-leptin</title>
            <description>Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
Metreleptin: Recombinant analog of the human hormone, leptin</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Insulin Sensitivity</title>
          <description>Total body insulin sensitivity (measured as glucose disposal rate during a hyperinsulinemic, euglycemic clamp)</description>
          <population>One patient at Period 2 (14 days) in Leptin naive arm was withdrew due to protocol violation.</population>
          <units>mg/kg fat-free mass/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intervention 1 (5 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.3"/>
                    <measurement group_id="O2" value="10.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intervention 2 (14 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.2"/>
                    <measurement group_id="O2" value="6.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-term follow-up (6 months)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin-mediated Suppression of Hepatic Glucose Production</title>
        <description>Hepatic insulin sensitivity (measured as suppression of endogenous glucose production during a hyperinsulinemic, euglycemic clamp)</description>
        <time_frame>Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)</time_frame>
        <population>Measurements were not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Leptin Naive</title>
            <description>Studied for 5 days without metreleptin, then 14 days while taking metreleptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
          </group>
          <group group_id="O2">
            <title>On-leptin</title>
            <description>Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
Metreleptin: Recombinant analog of the human hormone, leptin</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-mediated Suppression of Hepatic Glucose Production</title>
          <description>Hepatic insulin sensitivity (measured as suppression of endogenous glucose production during a hyperinsulinemic, euglycemic clamp)</description>
          <population>Measurements were not available.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intervention 1 (5 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="23.4"/>
                    <measurement group_id="O2" value="77.1" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intervention 2 (14 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="33.1"/>
                    <measurement group_id="O2" value="63.8" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-term follow-up (6 months)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endogenous Rate of Appearance of Palmitate</title>
        <description>Endogenous Rate of Appearance of Palmitate is measured in plasma.</description>
        <time_frame>Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)</time_frame>
        <population>Measurements were not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Leptin Naive</title>
            <description>Studied for 5 days without metreleptin, then 14 days while taking metreleptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
          </group>
          <group group_id="O2">
            <title>On-leptin</title>
            <description>Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
Metreleptin: Recombinant analog of the human hormone, leptin</description>
          </group>
        </group_list>
        <measure>
          <title>Endogenous Rate of Appearance of Palmitate</title>
          <description>Endogenous Rate of Appearance of Palmitate is measured in plasma.</description>
          <population>Measurements were not available.</population>
          <units>Î¼mol/kg fat-free mass/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intervention 1 (5 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.3"/>
                    <measurement group_id="O2" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intervention 2 (14 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.0"/>
                    <measurement group_id="O2" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Long-term follow-up (6 months)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention 1 (5 Days) : Leptin Naive</title>
          <description>Studied for 5 days without taking metreleptin.
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="E2">
          <title>Intervention 2 (14 Days): Leptin Naive</title>
          <description>Studied for 14 days while taking metreleptin after the intervention 1 (5 days) : Leptin Naive Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="E3">
          <title>Long-term Follow-up (6 Months): Leptin Naive</title>
          <description>Studied for 6 months while taking metreleptin after intervention 2 (14 days): Leptin Naive
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="E4">
          <title>Intervention 1 ( 5 Days) : On-Leptin</title>
          <description>Studied for 5 days while taking metreleptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
        <group group_id="E5">
          <title>Intervention 1 ( 14 Days): On-Leptin</title>
          <description>Studied for 14 days during metreleptin withdrawal after Intervention 1 ( 5 days) : On-Leptin
Metreleptin: Recombinant analog of the human hormone, leptin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angioedema secondary to angiotensin- converting enzyme inhibitor use</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>anemia secondary to menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain of unknown etiology</sub_title>
                <description>This adverse event was happened within 30 days window after the end of long-term follow-up.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>hypoglycemia (in a subject treated with insulin)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hair loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rebecca Brown</name_or_title>
      <organization>NIDDK</organization>
      <phone>301-594-0609</phone>
      <email>brownrebecca@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

